Usefulness of 6-minute walk test, plasma neurohumoral and cytokine activation in the assessment of symptomatic patients with left ventricle dysfunction caused by chronic severe mitral valve regurgitation

Acta Cardiologica

Volumn 65, Issue 1, 2010, Pages 43-51

  Leszek, Przemyslław ^a   Klisiewicz, Anna ^a   Janas, Jadwiga ^a   Biederman, Andrzej ^a   Piotrowski, Walerian ^a   Rywik, Tomasz ^a   Korewicki, Jerzy ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

6 minute walk test; Chronic mitral regurgitation; Cytokines; Neurohormones

Indexed keywords

ALDOSTERONE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CYTOKINE; INTERLEUKIN 6; NEUROHORMONE; NORADRENALIN; TUMOR NECROSIS FACTOR ALPHA;

6 MINUTE WALK TEST; ADULT; ARTICLE; CARDIOVASCULAR SYSTEM EXAMINATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CYTOKINE PRODUCTION; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HORMONE BLOOD LEVEL; HUMAN; MALE; MITRAL VALVE REGURGITATION; PLASMA RENIN ACTIVITY; PROTEIN BLOOD LEVEL; WALKING SPEED;

BIOLOGICAL MARKERS; BIOTRANSFORMATION; CHRONIC DISEASE; CYTOKINES; ECHOCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; PROGNOSIS; RADIOIMMUNOASSAY; RENIN-ANGIOTENSIN SYSTEM; SEVERITY OF ILLNESS INDEX; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING; WALKING;

EID: 77749252336     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.65.1.2045888     Document Type: Article

References (24)

1. Carabello BA. The ten most commonly asked questions about mitral regurgitation. Cardiol Rev 2002; 10: 321-2.
2. Detaint D, Messika-Zeitoun D, Avierinos JF, Scott C, Chen H, Burnett JC, Jr., Enriquez-Sarano M. B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation 2005; 111: 2391-7.
3. Yusoff R, Clayton N, Keevil B, Morris J, Ray S. Utility of plasma N-terminal brain natriuretic peptide as a marker of functional capacity in patients with chronic severe mitral regurgitation. Am J Cardiol 2006; 97: 1498-1501.
4. Tavel ME, Carabello BA. Chronic mitral regurgitation: when and how to operate. Chest 1998; 113: 1399-1401.
5. Kapadia SR, Yakoob K, Nader S, Thomas JD, Mann DL, Griffin BR Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 2000; 36: 208-12.
6. Carabello BA. Indications for mitral valve surgery. J Cardiovasc Surg (Torino) 2004; 45: 407-18.
7. Le Tourneau T, de Groote P, Millaire A, Foucher C, Savoye C, Pigny P, Prat A, Warembourg H, Lablanche JM. Effect of mitral valve surgery on exercise capacity, ventricular ejection fraction and neurohormonal activation in patients with severe mitral regurgitation. J Am Coll Cardiol 2000; 36: 2263-9.
8. Jourdain P, Funck F, Bellorini M, Guillard N, Loiret J, Thebault B, Desnos M, Duboc D. Bedside B-type natriuretic peptide and functional capacity in chronic heart failure. Eur J Heart Fail 2003; 5: 155-60.
9. Hirata Y, Matsumoto A, Aoyagi T, Yamaoki K, Komuro I, Suzuki T, Ashida T, Sugiyama T, Hada Y, Kuwajima I, Nishinaga M, Akioka H, Nakajima O, Nagai R, Yazaki Y Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload. Cardiovasc Res 2001; 51: 585-91.
10. Golbasy Z, Ucar O, Yuksel AG, Gulel O, Aydogdu S, Ulusoy V. Plasma brain natriuretic peptide levels in patients with rheumatic heart disease. Eur J Heart Fail 2004; 6: 757-60.
11. Watanabe M, Murakami M, Furukawa H, Nakahara H. Is measurement of plasma brain natriuretic peptide levels a useful test to detect for surgical timing of valve disease? Int J Cardiol 2004; 96: 21-4.
12. Mayer SA, De Lemos JA, Murphy SA, Brooks S, Roberts BJ, Grayburn PA. Comparison of B-type natriuretic peptide levels in patients with heart failure with versus without mitral regurgitation. Am J Cardiol 2004; 93: 1002-6.
13. Brookes CI, Kemp MW, Hooper J, Oldershaw PJ, Moat NE. Plasma brain natriuretic peptide concentrations in patients with chronic mitral regurgitation. J Heart Valve Dis 1997; 6: 608-12.
14. Sutton TM, Stewart RA, Gerber IL, West TM, Richards AM, Yandle TG, Kerr AJ. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 2003; 41: 2280-7.
15. Tanaka T, Hasegawa K, Fujita M, Tamaki SI, Yamazato A, Kihara Y, Nohara R, Sasayama S. Marked elevation of brain natriuretic peptide levels in pericardial fluid is closely associated with left ventricular dysfunction. J Am Coll Cardiol 1998; 31: 399-403.
16. Mehta RH, Supiano MA, Oral H, Grossman PM, Petrusha JA, Montgomery DG, Briesmiester KA, Smith MJ, Starling MR. Relation of systemic sympathetic nervous system activation to echocardiographic left ventricular size and performance and its implications in patients with mitral regurgitation. Am J Cardiol 2000; 86: 1193-7.
17. Mehta RH, Supiano MA, Oral H, Grossman PM, Montgomery DS, Smith MJ, Starling MR. Compared with control subjects, the systemic sympathetic nervous system is activated in patients with mitral regurgitation. Am Heart J 2003; 145: 1078-85.
18. Dzimiri N, Moorji A, Kumar M, Kumar N, Halees Z. Comparison of the effect of left ventricular volume and pressure overload on beta-adrenoceptor density in left heart valvular disease. Int J Cardiol 1996; 53: 109-16.
19. Mehta RH, Supiano MA, Grossman PM, Oral H, Montgomery DG, Briesmiester KA, Smith MJ, Starling MR. Changes in systemic sympathetic nervous system activity after mitral valve surgery and their relationship to changes in left ventricular size and systolic performance in patients with mitral regurgitation. Am Heart J 2004; 147: 729-35.
20. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). JAm Coll Cardiol 1996; 27: 1201-6.
21. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93: 704-11.
22. Boffa GM, Zaninotto M, Nalli C, Forni M, Tiso E, Razzolini R, Plebani M. Plasma levels of tumor necrosis factor-alpha correlate with the six-minute walk test results in patients with mild to moderate heart failure. Ital Heart J 2004; 5: 48-52.
23. Oral H, Sivasubramanian N, Dyke DB, Mehta RH, Grossman PM, Briesmiester K, Fay WP, Pagani FD, Boiling SF, Mann DL, Starling MR. Myocardial proinflammatory cytokine expression and left ventricular remodeling in patients with chronic mitral regurgitation. Circulation 2003; 107: 831-7.
24. Leszek P, Janas J, Klisiewicz A, Biederman A, Rywik T, Kopacz M, Browarek A, Korewicki J. Mitral valve regurgitation and plasma neurohumoral and cytokine activation. Acta Cardiol 2004; 59: 208-10.